[go: up one dir, main page]

WO2004011498A3 - Derives de peptide natriuretique de longue duree - Google Patents

Derives de peptide natriuretique de longue duree Download PDF

Info

Publication number
WO2004011498A3
WO2004011498A3 PCT/CA2003/001097 CA0301097W WO2004011498A3 WO 2004011498 A3 WO2004011498 A3 WO 2004011498A3 CA 0301097 W CA0301097 W CA 0301097W WO 2004011498 A3 WO2004011498 A3 WO 2004011498A3
Authority
WO
WIPO (PCT)
Prior art keywords
long lasting
natriuretic peptide
peptide derivatives
peptide
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2003/001097
Other languages
English (en)
Other versions
WO2004011498A2 (fr
Inventor
Dominique P Bridon
Peter Bakis
Julie Carette
France Leclaire
Roger Leger
Martin Robitaille
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ConjuChem Inc
Original Assignee
ConjuChem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2003246500A priority Critical patent/AU2003246500A1/en
Priority to CA002488348A priority patent/CA2488348A1/fr
Priority to EP03771007A priority patent/EP1530588A2/fr
Priority to US10/471,348 priority patent/US20040266673A1/en
Priority to JP2004523679A priority patent/JP2006514607A/ja
Application filed by ConjuChem Inc filed Critical ConjuChem Inc
Publication of WO2004011498A2 publication Critical patent/WO2004011498A2/fr
Publication of WO2004011498A3 publication Critical patent/WO2004011498A3/fr
Priority to US11/040,810 priority patent/US20050176641A1/en
Anticipated expiration legal-status Critical
Priority to US11/067,556 priority patent/US7601691B2/en
Priority to US11/923,222 priority patent/US7906482B2/en
Priority to US11/926,843 priority patent/US20080199532A1/en
Priority to US12/253,856 priority patent/US20090275506A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des dérivés de peptide natriurétique (NP) de longue durée. Le dérivé NP comprend un peptide NP et une entité réactive couplée au peptide NP. L'entité réactive peut se lier par covalence avec une fonctionnalité sur un composant sanguin. D'une manière plus spécifique, l'invention concerne des dérivés NP ayant une demi-vie in vivo prolongée ainsi qu'une méthode de traitement des maladies et des troubles cardio-vasculaires, tels que l'insuffisance cardiaque globale décompensée aiguë et l'insuffisance cardiaque globale chronique.
PCT/CA2003/001097 1999-05-17 2003-07-29 Derives de peptide natriuretique de longue duree Ceased WO2004011498A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AU2003246500A AU2003246500A1 (en) 2002-07-31 2003-07-29 Long lasting natriuretic peptide derivatives
CA002488348A CA2488348A1 (fr) 2002-07-31 2003-07-29 Derives de peptide natriuretique de longue duree
EP03771007A EP1530588A2 (fr) 2002-07-31 2003-07-29 Derives de peptide natriuretique de longue duree
US10/471,348 US20040266673A1 (en) 2002-07-31 2003-07-29 Long lasting natriuretic peptide derivatives
JP2004523679A JP2006514607A (ja) 2002-07-31 2003-07-29 長時間持続性ナトリウム排泄増加性ペプチド誘導体
US11/040,810 US20050176641A1 (en) 2000-05-17 2005-01-21 Long lasting natriuretic peptide derivatives
US11/067,556 US7601691B2 (en) 1999-05-17 2005-02-25 Anti-obesity agents
US11/923,222 US7906482B2 (en) 1999-05-17 2007-10-24 Anti-obesity agents
US11/926,843 US20080199532A1 (en) 1999-05-17 2007-10-29 Long Lasting Natriuretic Peptide Derivatives
US12/253,856 US20090275506A1 (en) 2000-05-17 2008-10-17 Long lasting natriuretic peptide derivatives

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40041302P 2002-07-31 2002-07-31
US40019902P 2002-07-31 2002-07-31
US60/400,199 2002-07-31
US60/400,413 2002-07-31

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/471,348 A-371-Of-International US20040266673A1 (en) 1999-05-17 2003-07-29 Long lasting natriuretic peptide derivatives
US11/040,810 Continuation US20050176641A1 (en) 1999-05-17 2005-01-21 Long lasting natriuretic peptide derivatives

Publications (2)

Publication Number Publication Date
WO2004011498A2 WO2004011498A2 (fr) 2004-02-05
WO2004011498A3 true WO2004011498A3 (fr) 2004-06-24

Family

ID=31191354

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2003/001097 Ceased WO2004011498A2 (fr) 1999-05-17 2003-07-29 Derives de peptide natriuretique de longue duree

Country Status (5)

Country Link
EP (1) EP1530588A2 (fr)
JP (2) JP2006514607A (fr)
AU (1) AU2003246500A1 (fr)
CA (1) CA2488348A1 (fr)
WO (1) WO2004011498A2 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7648962B2 (en) 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
US7662773B2 (en) 2002-11-26 2010-02-16 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
US8071560B2 (en) 2004-02-17 2011-12-06 University Of South Florida Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor
US8148114B2 (en) 2004-02-17 2012-04-03 University Of South Florida Materials and methods for treatment of inflammatory and cell proliferation disorders
US8623835B2 (en) 2002-09-06 2014-01-07 University Of South Florida Materials and methods for treatment of respiratory allergic diseases
US9173950B2 (en) 2012-05-17 2015-11-03 Extend Biosciences, Inc. Vitamin D-ghrelin conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
DK1360202T3 (da) 2001-02-16 2008-09-22 Conjuchem Biotechnologies Inc Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
EP1759001B1 (fr) 2004-04-21 2011-04-13 Enobia Pharma Inc. Conjugues de delivrance dans l'os et procede d'utilisation pour le ciblage de proteines vers l'os
EP1773867B1 (fr) 2004-07-15 2011-01-19 The University Of Queensland Composes proteiniques et leurs utilisations
EP1855661B1 (fr) * 2005-03-07 2011-05-04 mondoBIOTECH AG Formulation pour l'aviptadil
WO2006108686A2 (fr) * 2005-04-14 2006-10-19 Aic Agonistes bnp
WO2007041645A2 (fr) * 2005-10-03 2007-04-12 Scios Inc. Forme oxydee du bnp humain
JP5010913B2 (ja) * 2006-12-31 2012-08-29 寿子 小出 心房利尿ホルモンファミリー分子を活性物質として含有する組織再生製剤また該製剤をもちいる組織再生方法、および心房利尿ホルモンファミリー分子を活性物質として含有する発毛、増毛、育毛剤および皮膚組織修復改善剤また該製剤を用いる発毛、増毛、育毛促進方法および皮膚組織修復改善方法
KR20080098216A (ko) * 2007-05-04 2008-11-07 한미약품 주식회사 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체
CA2689492A1 (fr) * 2007-06-06 2008-12-18 Boehringer Ingelheim International Gmbh Proteines de fusion natriuretiques
CA2691898A1 (fr) * 2007-07-06 2009-01-15 Theratechnologies Inc. Proteines de fusion bifonctionnelles de l'hormone de stimulation des alpha-melanocytes (alpha-msh) et de la proteine natriuretique auriculaire (pna), et leurs utilisations dans l'hypertension et la lesion renale aigue
DE102010032482A1 (de) 2010-07-28 2012-02-02 Justus-Liebig-Universität Giessen Stoffe zur Beeinflussung der natriuretischen Peptid-Rezeptoren A und B und deren Verwendung
WO2012013597A1 (fr) 2010-07-28 2012-02-02 Justus-Liebig-Universität Giessen Substances et utilisation desdites substances pour influer sur les récepteurs peptidiques natriurétiques
AU2011350066A1 (en) 2010-12-27 2013-07-11 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
EP2678025B1 (fr) * 2011-02-23 2017-03-08 Madeleine Pharmaceuticals Pty Ltd Vsdl pour le traitement de l'insuffisance cardiaque décompensée aiguë
CN102286092B (zh) 2011-09-14 2014-01-01 深圳翰宇药业股份有限公司 利拉鲁肽的固相合成方法
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
ES3038086T3 (en) 2014-12-05 2025-10-09 Alexion Pharma Inc Treating seizure with recombinant alkaline phosphatase
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
US12221495B2 (en) * 2015-05-29 2025-02-11 Igisu Co., Ltd. Cyclic peptide and a medicament, external preparation and cosmetic comprising said cyclic peptide
JP6993961B2 (ja) 2015-08-17 2022-01-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼの製造
JP6868617B2 (ja) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
EP3368062A4 (fr) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. Méthodes de traitement de la craniosynostose chez un patient
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
WO2017173395A1 (fr) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Méthodes de traitement de l'hypophosphatasie chez les adolescents et les adultes
CA3019726A1 (fr) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Traitement d'une faiblesse musculaire a l'aide de phosphatases alcalines
EP3464573A4 (fr) 2016-06-06 2020-02-19 Alexion Pharmaceuticals, Inc. Impact du métal sur la production des phosphatases alcalines
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
EP3600383A4 (fr) 2017-03-31 2020-10-28 Alexion Pharmaceuticals, Inc. Méthodes de traitement de l'hypophosphatasie (hpp) chez l'adulte et l'adolescent
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
WO2020033867A2 (fr) 2018-08-10 2020-02-13 Alexion Pharmaceuticals, Inc. Procédés de traitement de la neurofibromatose de type 1 et d'états apparentés avec une phosphatase alcaline
JP2023504208A (ja) 2019-12-09 2023-02-01 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼポリペプチド及びその使用方法
BR112023016048A2 (pt) 2021-02-12 2023-11-14 Alexion Pharma Inc Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos
US20240174727A1 (en) 2022-10-21 2024-05-30 Eli Lilly And Company Long-acting natriuretic peptides and uses thereof
CN116284329B (zh) * 2023-04-28 2023-12-08 成都奥达生物科技有限公司 一种长效利钠肽化合物
CN119529033A (zh) * 2024-12-02 2025-02-28 中山大学 一种用于npr-b靶向的超长效多肽及其在骨骼系统病症中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069900A2 (fr) * 1999-05-17 2000-11-23 Conjuchem, Inc. Protection de peptides therapeutiques endogenes contre l'activite peptidase par conjugaison de composants sanguins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3042782B2 (ja) * 1985-11-05 2000-05-22 サイオス インコーポレイテッド 心房性ナトリウム尿排泄亢進ペプチド類似化合物
EP0223143A3 (fr) * 1985-11-05 1989-04-12 California Biotechnology, Inc. Analogues de peptides atriaux natriurétiques
EP0431113A4 (en) * 1989-05-24 1992-01-22 Abbott Laboratories Atrial peptide derivatives
CA2373252C (fr) * 1999-05-17 2007-08-07 Conjuchem Inc. Peptides antiangiogeniques durables
AU781380B2 (en) * 1999-09-07 2005-05-19 Conjuchem Biotechnologies Inc. Pulmonary delivery for bioconjugation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069900A2 (fr) * 1999-05-17 2000-11-23 Conjuchem, Inc. Protection de peptides therapeutiques endogenes contre l'activite peptidase par conjugaison de composants sanguins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEGER ROGER ET AL: "Synthesis and in vitro analysis of atrial natriuretic peptide-albumin conjugates.", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 13, no. 20, 20 October 2003 (2003-10-20), pages 3571 - 3575, XP001156881, ISSN: 0960-894X *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8623835B2 (en) 2002-09-06 2014-01-07 University Of South Florida Materials and methods for treatment of respiratory allergic diseases
US7662773B2 (en) 2002-11-26 2010-02-16 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
US7648962B2 (en) 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
US8071560B2 (en) 2004-02-17 2011-12-06 University Of South Florida Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor
US8148114B2 (en) 2004-02-17 2012-04-03 University Of South Florida Materials and methods for treatment of inflammatory and cell proliferation disorders
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
US9884124B2 (en) 2012-05-17 2018-02-06 Extend Biosciences, Inc. Carriers for improved drug delivery
US9173950B2 (en) 2012-05-17 2015-11-03 Extend Biosciences, Inc. Vitamin D-ghrelin conjugates
US9289507B2 (en) 2012-05-17 2016-03-22 Extend Biosciences, Inc. Carriers for improved drug delivery
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US10406202B2 (en) 2014-10-22 2019-09-10 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US10420819B2 (en) 2014-10-22 2019-09-24 Extend Biosciences, Inc. Insulin vitamin D conjugates
US10702574B2 (en) 2014-10-22 2020-07-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US11116816B2 (en) 2014-10-22 2021-09-14 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US12076366B2 (en) 2014-10-22 2024-09-03 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone

Also Published As

Publication number Publication date
JP2010047614A (ja) 2010-03-04
JP2006514607A (ja) 2006-05-11
EP1530588A2 (fr) 2005-05-18
WO2004011498A2 (fr) 2004-02-05
AU2003246500A1 (en) 2004-02-16
CA2488348A1 (fr) 2004-02-05

Similar Documents

Publication Publication Date Title
WO2004011498A3 (fr) Derives de peptide natriuretique de longue duree
WO2004066805A3 (fr) Dispositif in vivo destine a ameliorer la fonction ventriculaire diastolique
WO2009067639A3 (fr) Variantes de peptide natriurétique de type c
EP1408038A3 (fr) Dérivés d'imidazole et leur utilisation en tant qu'inhibiteurs périphère-sélectives de bèta-hydroxylase
EP1623994A3 (fr) Protection de peptides thérapeutiques endogènes contre l'activité peptidase par conjugaison de composants sanguins
AU2002313743A1 (en) Treatment of congestive heart failure and autonomic cardiovascular drive disorders
AU2003212961A1 (en) Split tip dialysis catheter
AU2002364142A1 (en) Treatments for a patient with congestive heart failure
AU2001251514A1 (en) Method for detecting cheyne-stokes respiration in patients with congestive heart failure
WO2006057920A3 (fr) Dispositifs, systemes et procedes de fabrication d'une fistule arterio-veineuse actionnee par energie
AU2003240833A1 (en) Low profile inlet for an implantable blood pump
AU2003258329A1 (en) Coronary vein navigator
WO2004021925A3 (fr) Prothese vasculaire notamment destinee a remplacer l'aorte ascendante
WO2002024108A3 (fr) Dispositif et introducteur servant a fournir un flux sanguin supplementaire
WO2004075857A3 (fr) Preparations, combinaisons, et procedes de traitement de pathologies cardio-vasculaires et autres etats associes
WO2001091826A3 (fr) Conception d'aiguille et procede de fabrication ameliores destines a des applications medicales
WO2004025270A3 (fr) Methodes permettant de mesurer les taux de transport inverse du cholesterol in vivo utilises comme indice d'anti-atherogenicite
WO2001003684A3 (fr) Composes liant l'albumine qui empechent la glycation non enzymatique et qui peuvent etre utilises dans le traitement de pathologies liees a la glycation
AU2003257187A1 (en) Dialysis catheters with optimized user-friendly connections
AU2002317172A1 (en) Tools for the diagnosis, molecular definition and development of treatment of chronic inflammatory joint diseases
CA2386215A1 (fr) Procede de traitement des insuffisances veineuses chroniques a l'aide d'un extrait de feuilles de vigne rouge
WO2002044113A3 (fr) Utilisation de derives d'acide acetique(-)(3-halomethylphenoxy)(4-halophenyl) dans le traitement de la resistance a l'insuline, le diabete de type 2, l'hyperlipidemie et l'hyperuricemie
AU2003278362A1 (en) Method of forward error correction
AU2003214210A1 (en) Treatment of congestive heart failure with natriuretic peptide and a diuretic
WO2005042063A8 (fr) Piece extra-aortique

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 10471348

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2488348

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003246500

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003771007

Country of ref document: EP

Ref document number: 2004523679

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003771007

Country of ref document: EP